In the trial, published in the New England Journal of Medicine, angiodema symptoms were reduced by 95% among a small group of patients from the UK, New Zealand, and the Netherlands given a single infusion – targeted at cells in the liver – to reduce the KLKB1 gene’s ability to produce plasma prekallikrein.
Trending
- DR Congo Ebola outbreak's true scale could be four times higher than official toll, WHO says
- Spain beat Argentina to win World Cup for second time
- Spain wins second World Cup after beating Argentina in final
- In the age of influencers and TikTok reviews, what is a critic even for?
- French heatwave threatens food inflation as agriculture sector suffers
- World’s biggest jackpot game Powerball to launch in UK this week
- The Odyssey Sails To $264 Million Global Box Office Opening
- Germany news: Merz moots Cabinet reshuffle after Spahn exit
